how could new treatment combinations improve outcomes in tp53 mutant aml?
Published 3 years ago • 228 plays • Length 9:24Download video MP4
Download video MP3
Similar videos
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
3:11
challenges in treating tp53-mutated aml, hope on the horizon
-
20:58
new findings and improved outcomes in the treatment of aml
-
23:04
tp53-mutant aml: a pathology-guided journey through diagnostic principles
-
6:46
how can venetoclax combinations improve outcome for flt3-mutant aml?
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
8:14
progress in the treatment of tp53 mutated aml
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:48
tp53-mutant aml linked to poorer outcomes with decitabine plus venetoclax
-
8:37
how can outcomes be improved in patients with molecularly-defined high-risk aml?
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
7:37
magrolimab in tp53-mutated aml and mds: what are the latest updates from eha2022?
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
1:39
treatment approaches for patients with tp53m aml ineligible for high intensity chemotherapy
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
1:27
treatment options for patients with tp53-mutated aml